MRMariana Michelle Ramírez-Mejía

Mariana Michelle Ramírez-Mejía

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Michelle Ramírez-Mejía has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic Dysfunction and Hepatocarcinogenesis: The Rising Burden of MASLD-Related HCC

    by Mariana M. Ramírez-Mejía, Mariana Montoya-López, Saraí Gómez-Camacho, Fernanda M. Martínez-Díaz, Elsie A. Jiménez-Cuevas, Nahum Méndez-Sánchez

    Metabolic dysfunction–associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) represents an emerging and increasingly prevalent cause of liver cancer worldwide, driven by the global epidemic of obesity, type 2 diabetes, and metabolic syndrome. Its hepatocarcinogenesis is multifactorial and involves lipotoxicity, chronic low-grade inflammation, gut dysbiosis, and genetic susceptibility, with complex and incompletely understood interactions among these pathways that converge to promote malignant hepatocyte transformation over years to decades. A distinctive feature is its development in the absence of cirrhosis in up to 38.5% of cases, creating a critical diagnostic gap that limits the effectiveness of current surveillance strategies, which were designed primarily for cirrhotic populations and therefore systematically exclude a substantial proportion of at-risk individuals who lack established fibrosis or portal hypertension. The clinical profile is characterized by late diagnosis, a higher tumor burden at presentation, and a more heterogeneous disease course, although preserved liver function in noncirrhotic patients paradoxically allows access to more aggressive surgical and locoregional treatments. Combined immunotherapy shows variable and often suboptimal efficacy due to the immunosuppressive hepatic microenvironment generated by chronic metabolic dysfunction, underscoring the urgent need for predictive biomarkers of treatment response and more refined patient selection criteria. Emerging evidence also implicates genetic polymorphisms and epigenetic dysregulation as key determinants of individual oncogenic risk that modulate both disease progression and therapeutic response across diverse populations. This chapter provides a comprehensive review of the epidemiology, pathogenesis, molecular risk factors, surveillance strategies, treatment options, and future perspectives of HCC associated with MASLD.

  • Open Access

    The interplay of insulin resistance, glycemic variability, and metabolic dysfunction-associated steatotic liver disease

    by Fernanda M. Martínez-Díaz, Elsie A. Jiménez-Cuevas, Mariana M. Ramírez-Mejía, Sarai Gómez-Camacho, Nahum Méndez-Sánchez

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic metabolic disorder closely related to insulin resistance, obesity, and type 2 diabetes mellitus. While sustained hyperglycemia and insulin resistance are central to the pathogenesis of MASLD, there is growing evidence suggesting that glucose dysregulation in this condition is heterogeneous and dynamic. Glycemic variability (GV), which reflects fluctuations in glucose levels over time, has emerged as a complementary dimension of glucose homeostasis and has been increasingly explored in relation to hepatic steatosis, fibrosis, and cardiometabolic risk. Experimental data indicate that recurrent glucose oscillations promote oxidative stress, inflammatory signaling, and fibrogenic activation, while observational studies have reported associations between short- and long-term GV and MASLD-related phenotypes in diverse populations. The aim of this review is to describe the mechanistic links between insulin resistance, GV, and MASLD, summarize the current clinical and population evidence evaluating GV in this context, and identify key methodological and conceptual gaps that should inform future research.


  • Open Access

    Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review

    by Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic condition with a complex pathophysiology involving multiple organs. Organokines, including hepatokines, myokines, cardiokines, renokines, osteokines, and adipokines, play central roles in lipid metabolism, glucose homeostasis, inflammation, and fibrosis. Dysregulation of these signaling molecules contributes to the progression of MASLD and its systemic complications. This review examines the role of organokine-mediated crosstalk between the liver and peripheral organs (e.g., muscle, heart, kidneys, bone, and adipose tissue) in the pathogenesis of MASLD. Key molecules, such as myostatin, FGF-21, IL-6, and adiponectin, influence insulin sensitivity, lipid metabolism, and inflammation. Some organokines have protective effects (e.g., FGF-21, irisin, and klotho), while others, such as myostatin and fetuin-A, exacerbate insulin resistance and fibrosis. These findings suggest that targeting organokines could provide potential biomarkers and therapeutic strategies for MASLD. Future research should focus on elucidating the molecular mechanisms and assessing the role of organokines in the prevention and treatment of MASLD.


  • Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets

    by Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Nahum Méndez-Sánchez


  • Open Access

    How the gut-liver axis shapes hepatic encephalopathy: mechanistic and therapeutic perspectives

    by Arnulfo E. Morales-Galicia, Mariana N. Rincón-Sánchez, Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez

    Hepatic encephalopathy (HE) is a debilitating neuropsychiatric complication of liver dysfunction that spans a continuum from subtle cognitive impairment to deep coma. While historically attributed to hyperammonemia, current insights reveal a multifactorial pathogenesis involving systemic inflammation, astrocyte dysfunction, blood-brain barrier (BBB) disruption, and altered neurotransmission. Central to this complex network is the gut-liver axis—a bidirectional system that links the gut microbiota, intestinal barrier integrity, bile acid metabolism, and hepatic immune responses. In cirrhosis, dysbiosis and increased intestinal permeability facilitate the translocation of microbial products—such as endotoxins and ammonia—that trigger hepatic and systemic immune activation, amplifying neurotoxicity through the gut-liver-brain axis. Experimental and clinical evidence has shown that ammonia and bilirubin synergistically promote neuroinflammation, mitochondrial dysfunction, and glial activation. Multiomics data further support the role of the microbiota as an active modulator of liver-brain homeostasis. Microbiota-targeted therapies—including rifaximin, probiotics, synbiotics, and fecal microbiota transplantation (FMT)—demonstrate efficacy in reducing HE recurrence, improving cognition, and restoring microbial balance. Novel receptor-based strategies targeting the farnesoid X receptor (FXR), Takeda G-protein-coupled receptor 5 (TGR5), and aryl hydrocarbon receptor (AhR) show promise for modulating bile acid pathways and mitigating neuroinflammation. Emerging approaches also focus on dietary interventions, the reinforcement of epithelial barrier function, and artificial intelligence (AI)-driven tools for personalized monitoring. Despite these advances, challenges persist regarding FMT standardization, long-term safety, and the integration of digital diagnostics into routine care.


  • Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications

    by Mariana M. Ramírez‐Mejía, Sandra M. Barbalho, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Jacob George, Ming‐Hua Zheng, Nahum Méndez‐Sánchez

    Background and Aims: Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease worldwide. Metabolic syndrome (MetS) has traditionally been used as an indicator to define metabolic dysfunction, but it may not fully reflect the risk spectrum of MASLD, underscoring the need to better understand its clinical heterogeneity. The aim of this study was to explore phenotypic heterogeneity within MASLD, in particular its overlap and divergence from MetS to improve clinical stratification. Methods: We applied an unsupervised clustering approach in a discovery cohort of 600 adults recruited through a local health screening programme, using standardised clinical and metabolic variables to identify distinct phenotypes. Associations between clustering, MASLD and MetS were assessed. External validation was performed on an independent cohort of 407 individuals using cluster centroids derived from the discovery cohort. Results: In the two‐cluster model, we identified a low‐risk group with favourable profiles and a high‐risk group enriched for MASLD and MetS. The three‐cluster model further refined these patterns, revealing an intermediate group characterised by MASLD without MetS, with heterogeneous yet clinically relevant metabolic features. Cluster structures were preserved in the validation cohort. Cluster membership was significantly associated with steatosis and liver fibrosis parameters. Conclusions: Our findings underscore the phenotypic heterogeneity of MASLD and its partial divergence from MetS. As MetS may not fully capture the spectrum of metabolic dysfunction in MASLD, phenotype‐based approaches grounded in clinical and metabolic data may enhance risk stratification and support more individualised management strategies.


  • Top Cited Papers
    Open Access

    The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review

    by Mariana M. Ramírez-Mejía, Stephany M. Castillo-Castañeda, Shreya C. Pal, Xingshun Qi, Nahum Méndez-Sánchez

    Bilirubin, the primary breakdown product of hemoproteins, particularly hemoglobin, plays a key role in the diagnosis, prognosis, and monitoring of liver diseases. In acute liver diseases, such as acute liver failure, drug-induced liver injury, and viral hepatitis, bilirubin serves as a biomarker reflecting the extent of hepatocyte loss and liver damage. Chronic liver diseases, including alcohol-related liver disease, chronic hepatitis C virus infection, metabolic dysfunction-associated fatty liver disease, and autoimmune liver diseases, are marked by persistent liver injury and inflammation. Bilirubin levels in chronic liver diseases provide insight into liver function, disease severity, and prognosis. As a versatile biomarker, bilirubin offers valuable information on the pathophysiology of liver diseases and aids in guiding clinical decision-making regarding the treatment of liver diseases and their complications. This review aimed to explore the multifunctional role of bilirubin in liver diseases by analyzing its biological functions beyond its role as a biomarker of liver damage.


  • Open Access

    Bilirubin Molecular Species Play an Important Role in the Pathophysiology of Acute-on-Chronic Liver Failure

    by Stephany M. Castillo-Castañeda, Jacqueline Cordova-Gallardo, Liliana Rivera-Espinosa, Juan L. Chavez-Pacheco, Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez

    Bilirubin plays a key role in early diagnosis, prognosis, and prevention of liver diseases. Unconjugated bilirubin (UCB) requires conversion to a water-soluble form through liver glucuronidation, producing monoglucuronide (BMG) or diglucuronide bilirubin (BDG) for bile excretion. This study aimed to assess the roles of bilirubin’s molecular species—UCB, BMG, and BDG—in diagnosing and understanding the pathogenesis of liver cirrhosis in patients with acute-on-chronic liver failure (ACLF), compensated liver cirrhosis (LC) patients, and healthy individuals. The study included patients with ACLF and compensated LC of diverse etiologies, along with healthy controls. We collected laboratory and clinical data to determine the severity and assess mortality. We extracted bilirubin from serum samples to measure UCB, BMG, and BDG using liquid chromatography–mass spectrometry (LC-MS). The quantification of bilirubin was performed by monitoring the mass charge (m/z) ratio. Of the 74 patients assessed, 45 had ACLF, 11 had LC, and 18 were healthy individuals. Among ACLF patients, the levels of molecular species of bilirubin were UCB 19.69 μmol/L, BMG 47.71 μmol/L, and BDG 2.120 μmol/L. For compensated cirrhosis patients, the levels were UCB 11.29 μmol/L, BMG 1.49 μmol/L, and BDG 0.055 μmol/L, and in healthy individuals, the levels were UCB 6.42 μmol/L, BMG 0.52 μmol/L, and BDG 0.028 μmol/L. The study revealed marked elevations in the bilirubin species in individuals with ACLF compared to those with compensated cirrhosis and healthy controls, underscoring the progression of liver dysfunction. The correlation of BMG and BDG levels with commonly used inflammatory markers suggests a relationship between bilirubin metabolism and systemic inflammation in ACLF.


  • Open Access

    Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals

    by Nahum Méndez-Sánchez, Carlos E. Coronel-Castillo, Mariana Michelle Ramírez-Mejía

    Chronic hepatitis C virus infection is an important cause of liver cirrhosis, hepatocellular carcinoma and death. Furthermore, it is estimated that about 40–70% of patients develop non-hepatic alterations in the course of chronic infection. Such manifestations can be immune-related conditions, lymphoproliferative disorders and metabolic alterations with serious adverse events in the short and long term. The introduction of new Direct-Acting Antivirals has shown promising results, with current evidence indicating an improvement and remission of these conditions after a sustained virological response.


  • Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?

    by Mariana Michelle Ramírez-Mejía, Carlos Jiménez-Gutiérrez, Mohammed Eslam, Jacob George, Nahum Méndez-Sánchez

    Background The classification and nomenclature of non-alcoholic fatty liver disease (NAFLD) has been the subject of ongoing debate in the medical community. Through the introduction of metabolic dysfunction-associated fatty liver disease (MAFLD) and the later release of metabolic dysfunction-associated steatotic liver disease (MASLD), the limitations associated with NAFLD are intended to be addressed. Both terminologies incorporate the metabolic component of the disease by providing diagnostic criteria that relies on the presence of underlying metabolic risk factors. Materials and Methods An epidemiologic cross-sectional study of individuals who had undergone abdominal ultrasound and vibration-controlled transient elastography (VCTE) as part of a routine check was performed. We evaluated clinical, anthropometric, and biochemical variables to determine the metabolic profile of each subject. Results The study included a total of 500 participants, 56.8% (n = 284) males and 43.2% (n = 216) females, with a mean age of 49 ± 10 years. 59.4% (n = 297) were diagnosed with MAFLD and MASLD, 10.2% (n = 51) were diagnosed only with MASLD and 30.4% (n = 152) were not diagnosed with either MAFLD or MASLD. The differences in prevalence were mainly based on the detection of individuals with a BMI < 25 kg/m2, where MASLD captures the largest number (p < 0.001). Conclusions Although MASLD has a higher capture of lean patients compared to MAFLD, patients with MAFLD and MASLD have a worse metabolic profile than those with only MASLD. Our results provide evidence that MAFLD better identifies patients likely to have a higher risk of liver fibrosis and of disease progression. Graphical abstract